Scaling from early discovery to full clinical trials is probably one of the most exciting — and often the most challenging — transitions for small biotechs. Getting that molecule to trial, filing the IND is a huge milestone. As your science advances, so must the systems, documentation, and oversight that ensure data integrity and regulatory compliance. This is uncharted territory for so many new biotechs. Are you ready for this next stage of development?
Growing Biotechs can underestimate how quickly operational gaps can turn into compliance risks, and can be very costly. The average operational cost for a day of delay in a phase 3 trial is approximately $50,000. Here are three of the most common pitfalls small biotechs face as they scale clinical operations — and we also share some simple, yet critical steps on how to avoid them.
1. 📝 Inadequate Documentation and Quality Systems (GCP/GMP Foundation)
Small biotechs often rely on informal processes or minimal quality oversight during early discovery. When moving into clinical trials, the game changes. As development moves into clinical stages, formalizing documentation under Good Clinical Practice (GCP) for trials and Good Manufacturing Practice (GMP) for drug production becomes essential. This is where business leaders need to shift from their “move fast and break things” mentality to the compliance “geeks” that dot every regulatory “i” and cross every quality assurance “t.”
The Risk: Failing to establish and start from day one with strong Quality Management System (QMS), Standard Operating Procedures (SOPs), and a robust Training Matrix can result in a cascade of delays, queries and data issues down the road. When the FDA or EMA audits a Phase 2 or 3 trial, auditors expect the same meticulous documentation rigor seen in large pharmaceutical companies. Be ready!
The consequences of not starting on the right footing can result in data integrity issues, missing regulatory documents and difficulty recreating trial history due to missing documents, and potential form 483 observations or FDA Warning Letters — any of which can halt development and dramatically delay the approval process.
2. 🕵️ Poor Vendor Management and Oversight (CROs and Suppliers)
As trials expand, small biotechs often outsource execution to Contract Research Organizations (CROs), central labs, and specialized vendors. This practice is common to bring on greater expertise. The caveat to this practice, however, is that the sponsor of the trial (the biotech) retains full responsibility for data integrity and regulatory compliance.
The Risk: Insufficient due diligence when selecting vendors — and critically, a lack of active oversight once the contract is signed. Small sponsors often assume the CRO is “handling everything” without performing ongoing monitoring or auditing of the vendor’s activities.
The Consequence: Non-compliance findings traceable back to the biotech sponsor, budget overruns from mismanagement, and loss of control over critical trial data and documentation processes.
3. 💾 Data Integrity and Regulatory Reporting Deficiencies
As operations scale, data volume multiplies across sites and systems — often involving multiple Electronic Data Capture (EDC) platforms. Regulators scrutinize the accuracy, consistency, and reliability of this data above all else.
The Risk: Inconsistent data collection standards across sites, failure to implement a comprehensive Data Management Plan, and errors in safety or regulatory reporting (such as Serious Adverse Events or SUSARs). These gaps often stem from teams lacking specialized regulatory training.
The Consequence: Difficulty locking databases, complications during statistical analysis, and even regulatory rejection of the submission package if data integrity cannot be verified — leading to major delays or clinical holds.
Building a strong foundation in GCP, vendor oversight, and data management isn’t just about compliance — it’s about ensuring every piece of research stands up to regulatory scrutiny and contributes meaningfully to medical progress.
Whether you’re a sponsor, site, or CRO professional, understanding these pitfalls is the first step to avoiding them. Contact us to learn how we can upskill your team!